Skip to content

Blog

Latest articles, insights, and updates from the blog.

113 articles

Contact Ketamine Tablet

Send corrections, provider questions, or advertising inquiries.

News1 min read

NMDA Antagonist Side Effects: What Tablet Users Should Know

New research in Psychiatric Times breaks down side effect profiles and discontinuation rates for NMDA antagonists — here's what it means for oral ketamine tablet users.

News1 min read

Ketamine Side Effects & Dropout Rates: What Data Says

New analysis in Psychiatric Times urges data-driven ketamine dosing. Here's what the side-effect and dropout data means for oral tablet users.

News1 min read

Glutamate Pathway Treatments Reshape TRD Care in 2026

New research highlights how glutamate-targeting drugs like esketamine and ketamine are reshaping treatment-resistant depression care. Here's what it means for oral ketamine users.

News1 min read

Faster TRD Remission: What Dose Optimization Means

New clinical guidance on TRD care emphasizes rapid dose adjustment and symptom tracking — here's what it means for oral ketamine tablet patients.

News1 min read

Glutamate Pathway Treatments Reshaping TRD Care

New research highlights glutamate-based therapies like esketamine and ketamine tablets for treatment-resistant depression. Here's what it means for oral ketamine users.

News1 min read

Insurance Gaps Push Patients Toward Oral Ketamine

Ketamine insurance claim denied? How oral ketamine tablets offer an affordable depression treatment path, plus appeals tips and cash-pay tablet pricing.

News1 min read

How Doctors Choose TRD Treatments in 2026

How clinicians choose ketamine treatments for treatment-resistant depression in 2026, including when oral tablets are picked over IV, IM, or nasal spray.

News1 min read

Esketamine for Treatment-Resistant Depression in 2026

Esketamine (Spravato) for treatment-resistant depression compared to ketamine tablets: efficacy, monitoring, cost, and which oral or nasal option fits.

News1 min read

Glutamate Pathway Drugs Are Reshaping TRD Care

How ketamine acts on the glutamate pathway in treatment-resistant depression and why oral tablet therapy targets the same NMDA receptors as IV ketamine.

News1 min read

Why Remission—Not Just Relief—Changes Ketamine Care

New clinical guidance pushes beyond symptom reduction toward full remission in TRD. Here's what that means for oral ketamine tablet users.

News1 min read

Ketamine's Role in Treatment-Resistant Depression Care

Psychiatric Times highlights ketamine among top TRD approaches. Here's what oral ketamine tablet users need to know about access and dosing.

News1 min read

BPL-003 Shows Sustained TRD Relief in Phase 2a Trial

Beckley Psytech's BPL-003 phase 2a part 2 data shows lasting symptom reduction in treatment-resistant depression — what it means for the TRD landscape.